You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 145 No. 11, November 2009 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Study
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Dermatologic Disorders
 •Randomized Controlled Trial
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Topical Calcipotriol for Preventive Treatment of Hypertrophic Scars

A Randomized, Double-blind, Placebo-Controlled Trial

Willem M. van der Veer, MS; Xander E. Jacobs, MD; Ingmar E. Waardenburg, MD; Magda M. Ulrich, PhD; Frank B. Niessen, MD, PhD

Arch Dermatol. 2009;145(11):1269-1275.

Objectives  To evaluate the efficacy of topical application of calcipotriol to healing wounds in preventing or reducing hypertrophic scar formation and to investigate the biochemical properties of the epidermis associated with hypertrophic scar formation.

Design  Randomized, double-blind, placebo-controlled trial using the reduction mammoplasty wound-healing model.

Setting  University Medical Center Groningen.

Patients  Thirty women who underwent bilateral reduction mammoplasty.

Interventions  For 3 months, scar segments were treated with either topical calcipotriol or placebo.

Main Outcome Measures  Three weeks, 3 months, and 12 months postoperatively, the scars were evaluated and punch biopsy samples were collected for immunohistochemical analysis.

Results  No significant difference in the prevalence of hypertrophic scars was observed between the placebo- and calcipotriol-treated scars. Only scars with activated keratinocytes 3 weeks postoperatively became hypertrophic (P = .001).

Conclusions  Topical application of calcipotriol during the first 3 months of wound healing does not affect the incidence of hypertrophic scar formation. We observed a strong association between keratinocyte activation and hypertrophic scar formation.

Trial Registration  trialregister.nl Identifier: NTR1486


Author Affiliations: Department of Plastic and Reconstructive Surgery, VU University Medical Center, Amsterdam (Mr van der Veer and Drs Jacobs, Ulrich, and Niessen); Department of Plastic and Reconstructive Surgery, University Medical Center Groningen, Groningen (Dr Waardenburg); and Association of Dutch Burn Centers, Beverwijk (Dr Ulrich), the Netherlands.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Dermatology
Arch Dermatol. 2009;145(11):1221.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.